An Underground Storage Tank Integrated Demonstration report. Volume 1, Waste Characterization Data and Technology Development Needs Assessment

The Waste Characterization Data and Technology Development Needs Assessment provides direct support to the Underground Storage Tank Integrated Demonstration (UST-ID). Key users of the study`s products may also include individuals and programs within the US Department of Energy (DOE) Office of Technology Development (EM-50), the Office of Waste Operations (EM-30), and the Office of Environmental Restoration (EM-40). The goal of this work is to provide the UST-ID with a procedure for allocating funds across competing characterization technologies in a timely and defensible manner. It resulted in three primary products: 1. It organizes and summarizes information on underground storage tank characterization data needs. 2. It describes current technology development activity related to each need and flags areas where technology development may be beneficial. 3. It presents a decision process, with supporting software, for evaluating, prioritizing, and integrating possible technology development funding packages. The data presented in this document can be readily updated as the needs of the Waste Operations and Environmental Restoration programs mature and as new and promising technology development options emerge

Setting the Foundation for Transforming the U.S. Energy System

Setting the Foundation for Transforming the U.S. Energy System: Three Federal Action Plans for Near- and Long-term Success is a short document written for the incoming U.S. Federal Administration's Transistion Team. The document represents what we believe to be foundational elements of a broad campaign to make rapid progress towards these goals for the longterm transformation necessary to meet our national economic, security, and environmental goals. The three immediate action plans include: * Creating Tomorrow’s Electricity Infrastructure * Decarbonizing the Energy Economy *Enabling Science-Based Polic

Otimismo comparativo e percepções de controle face à saúde na adolescência: existirão diferenças etárias?

O Otimismo Comparativo (OC), a tendência da maioria das pessoas para ver o seu futuro como mais positivo que o futuro dos outros, e a sua relação com a Percepção de Controle estão pouco estudados na adolescência. Os objetivos deste estudo prenderam-se com a análise das diferenças etárias na adolescência: (1) no OC e Percepções Comparativas de Controle (PCC) face a riscos para a saúde e (2) na forma como as Percepções Absolutas e Comparativas de Controle predizem o OC. Noventa e um pré-adolescentes (M = 11,92 anos) e 97 adolescentes (M = 16,86 anos) saudáveis efectuaram julgamentos de risco e controle (Próprio vs. Alvo) para 8 enfermidades. Os participantes mostraram-se comparativamente otimistas, julgando ter maior controle sobre algumas doenças que o alvo. Não existiram diferenças etárias no OC ou nas PCCs. Estas foram o principal preditor do OC, mediando a relação entre este e as Percepções Absolutas de Controle apenas na sub-amostra dos adolescentes.Comparative Optimism (CO) is the tendency for most people to perceive their future as rosier than the future of others. Such optimistic bias and its relationship with Perceived Control have seldom been studied among adolescents. Hence, this study aimed at exploring age differences throughout adolescence in: 1) CO and Comparative Perceived Control (CPC) over health hazards; 2) the way Absolute and Comparative Perceived Control account for CO. Ninety-one pre-adolescents (M = 11.92 years) and 97 adolescents (M = 16.86 years), all considered healthy, were asked for risk and control judgements (Self vs. Target) regarding 8 health hazards. Generally, participants were comparatively optimistic and saw themselves as having more personal control over some hazards than the target. No age differences were found in CO or CPC. The latter was the best predictor of CO for both cohorts. It mediated the relationship between Absolute Perceived Control and CO in the older participants' sample

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

BACKGROUND: The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. METHODS: In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 patients who had at least one of the following conditions: an acute coronary syndrome within the previous 30 to 365 days, cerebrovascular atherosclerotic disease, peripheral vascular arterial disease, or diabetes mellitus with coronary artery disease. Patients were randomly assigned to receive either evacetrapib at a dose of 130 mg or matching placebo, administered daily, in addition to standard medical therapy. The primary efficacy end point was the first occurrence of any component of the composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina. RESULTS: At 3 months, a 31.1% decrease in the mean LDL cholesterol level was observed with evacetrapib versus a 6.0% increase with placebo, and a 133.2% increase in the mean HDL cholesterol level was seen with evacetrapib versus a 1.6% increase with placebo. After 1363 of the planned 1670 primary end-point events had occurred, the data and safety monitoring board recommended that the trial be terminated early because of a lack of efficacy. After a median of 26 months of evacetrapib or placebo, a primary end-point event occurred in 12.9% of the patients in the evacetrapib group and in 12.8% of those in the placebo group (hazard ratio, 1.01; 95% confidence interval, 0.91 to 1.11; P=0.91). CONCLUSIONS: Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease. (Funded by Eli Lilly; ACCELERATE ClinicalTrials.gov number, NCT01687998 .)

Myopia, regrets, and risky behaviors

This paper examines how a government should intervene when agents make choices having long-term detrimental effects on their life expectancy. For that purpose, we consider an economy where some agents consume a sin good (reducing their survival chances) out of myopia, and regret their choices later on, whereas other agents make, because of their impatience, the same risky choices, which they never regret. We argue that, in the first-best, a government should only interfere with behaviors that agents will regret, but not with other behaviors. In the second-best, asymmetric information and redistributive concerns imply interferences not only with myopic behaviors, but also with impatience-based (rational) behaviors. Finally, we introduce heterogeneity in individual earnings, and show that the optimal tax on the sin good depends on the size of the myopic group, on the reactivity of sin good consumption to tax changes, and on the extent to which sin good consumption is correlated with labor earnings

Setting the Foundation for Transforming the U.S. Energy System

Setting the Foundation for Transforming the U.S. Energy System: Three Federal Action Plans for Near- and Long-term Success is a short document written for the incoming U.S. Federal Administration's Transistion Team. The document represents what we believe to be foundational elements of a broad campaign to make rapid progress towards these goals for the longterm transformation necessary to meet our national economic, security, and environmental goals. The three immediate action plans include: * Creating Tomorrow’s Electricity Infrastructure * Decarbonizing the Energy Economy *Enabling Science-Based Polic